LALPATHLAB Stock Analysis

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>DL</div>
LALPATHLAB -- India Stock  

INR 1,571  46.85  2.90%

Is it time to take up DR LAL? DR LAL Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The latest increase in of DR LAL PATHLABS short term price appreciation may encourage investors to take a closer look at the firm as it closed today at a share price of 1564.95 on 46,088 in trading volume. The company executives have been quite successful with maneuvering the fund at opportune times to take advantage of all market conditions in June. The stock standard deviation of daily returns for 30 days investing horizon is currently 2.05. The current volatility is consistent with the ongoing market swings in June 2020 as well as with DR LAL PATHLABS unsystematic, company-specific events. Additionally, see Stocks Correlation.

Search Stock Analysis

The DR LAL Stock analysis interface makes it easy to digest most current publicly released information about DR LAL as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. LALPATHLAB stock analysis module also helps to analyze DR LAL price relationship with some important fundamental indicators such as market cap and management efficiency.

LALPATHLAB Stock Analysis Notes

About 60.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 2.03. DR LAL PATHLABS recorded earning per share (EPS) of 27.37. The entity last dividend was issued on the 5th of March 2020. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India. DR LAL operates under Diagnostics Research classification in India and is traded on National Stock Exchange of India. To find out more about N/A contact the company at 91 12 4301 6500 or learn more at

DR LAL PATHLABS Investment Alerts

About 60.0% of the company outstanding shares are owned by corporate insiders

Market Capitalization

The company currently falls under 'Mega-Cap' category with current market capitalization of 130.73 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DR LAL's market, we take the total number of its shares issued and multiply it by DR LAL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.


The company has Profit Margin (PM) of 16.98 %, which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 20.35 % which suggests for every 100 dollars of sales it generated a net operating income of 0.2.

Management Efficiency

The entity has return on total asset (ROA) of 13.73 % which means that it generated profit of $13.73 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 22.7 %, meaning that it generated $22.7 on every $100 dollars invested by stockholders. DR LAL management efficiency ratios could be used to measure of how well dr lal pathlabs is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.

Technical Drivers

As of the 5th of July, DR LAL owns the market risk adjusted performance of 0.9612, downside deviation of 2.95, and standard deviation of 2.7. In connection with fundamental indicators, the technical analysis model provides you with a way to check timely technical drivers of DR LAL PATHLABS, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to analyze nineteen technical drivers for DR LAL, which can be compared to its peers in the sector. Please confirm DR LAL PATHLABS downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if DR LAL PATHLABS is priced fairly, providing market reflects its prevailing price of 1570.9 per share.

DR LAL PATHLABS Price Movement Analysis

The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. DR LAL middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for DR LAL PATHLABS. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

DR LAL Predictive Indicators

DR LAL Forecast Models

About DR LAL Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how DR LAL stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling LALPATHLAB shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as DR LAL. By using and applying LALPATHLAB Stock analysis, traders can create a robust methodology for identifying LALPATHLAB entry and exit points for their positions.
Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India. DR LAL operates under Diagnostics Research classification in India and is traded on National Stock Exchange of India.

Did you try this?

Run Pattern Recognition Now


Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module
Additionally, see Stocks Correlation. Please also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page